Satellos Bioscience Stock
Satellos Bioscience Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Francis Gleeson
- Employees
- 18
- Market cap
- $8 M
- IPO
- 03/08/2012
- Web
- satellos.com
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral,…
Satellos Bioscience stock: price history
1D
-5.6%
1W
-13.8%
1M
-30.5%
6M
-25.7%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~22% weaker price swings than usual
Ask the agents about Satellos Bioscience
Analyst assessment of Satellos Bioscience
PRICE TARGET LOW
US$18.00
CONSENSUS
US$20.75
MEDIAN
US$20.50
PRICE TARGET HIGH
US$24.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 17/08/2026
Satellos Bioscience stock metrics
P/E
-3.3
P/B
2.28
EV/EBITDA
-3.66
RETURN ON EQUITY
-19.1%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.6%
FLOAT SHARES
1,063,990
AVG. DAILY VOLUME (30D)
59,661
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Satellos Bioscience stock
What does Satellos Bioscience do?
Satellos Bioscience Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Francis Gleeson, the company employs around 18 people.
The IPO was on 03/08/2012; the stock trades on NASDAQ under the ticker MSLE.
What do analysts say about Satellos Bioscience stock?
1 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$20.75, ranging from US$18.00 to US$24.00, with a median of US$20.50.
This is an external assessment, not a statement by Market Jury.
When does Satellos Bioscience report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
Does Satellos Bioscience pay a dividend?
No, Satellos Bioscience currently does not pay a dividend.
Which stocks are comparable to Satellos Bioscience?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Satellos Bioscience stock analyzed?
Clicking "Analyze stock" lets five strategies assess Satellos Bioscience against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.